2023-11-22 08:00:00
DECRYPTION – Derived from the antidiabetic drug Ozempic, it was widely acclaimed on social networks as well as by American stars wishing to refine their silhouette. It will be subject to a strictly regulated prescription to prevent use for aesthetic purposes.
It is not a miracle solution, but still an immense hope for the 8.5 million people suffering obesity In France. Wegovy, a drug from Danish pharmaceutical giant Novo Nordisk, should soon be available on the market. Popularized on social networks under the name Ozempic – its equivalent dedicated to diabetes -, “Wegovy has obtained its marketing authorization and its price is now under discussion at the High Authority of Health», entrusts to Figaro the National Medicines Safety Agency (ANSM).
This weight loss drug, already available since 2021 in the United States, shows quite spectacular effectiveness in a context where treatment options for obesity remain limited. The drug causes patients to lose 5 to 20% of their weight (15 kilos on average) after one year of treatment. Very attractive results, which make health authorities fear misuse on the part of people who would only like to lose a few…
This article is reserved for subscribers. You have 89% left to discover.
Black Friday
-70% on digital subscription
Already subscribed? Log in
#Wegovy #revolutionary #treatment #obesity #finally #arriving #France